European Journal of Cancer

• 

  Publication Venue For

  • Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools..  143:147-157. 2021
  • Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients.  138:S9-S10. 2020
  • MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit..  138:S6. 2020
  • Epigenetic assay detects early stage non-small cell lung cancer in sputum.  49:S36-S36. 2013
  • The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium..  47:1373-1379. 2011
  • A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas..  46:3287-3293. 2010
  • Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL..  46:1848-1855. 2010
  • GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis..  46:1617-1631. 2010
  • Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study..  45:1603-1615. 2009
  • Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study..  45:8-11. 2009
  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours..  42:2433-2453. 2006
  • Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy..  40:205-211. 2004
  • A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care..  36 Suppl 1:S15-S21. 2000
  • E-selectin can mediate the arrest type of adhesion of colon cancer cells under physiological shear flow..  36:121-127. 2000
  • Gliomas..  34:1910-1915. 1998
  • The economics of febrile neutropenia: implications for the use of colony-stimulating factors..  34:1857-1864. 1998
  • Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients..  33:2315-2320. 1997
  • Basic population and cancer genetics and their use in the assessment of cancer risk..  33:2160-2166. 1997
  • Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group..  33:2121-2125. 1997
  • Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma..  33:1900-1902. 1997
  • Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts..  32A:2394-2400. 1996
  • Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma..  31A:576-581. 1995
  • Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas..  30A:1096-1099. 1994
  • Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience..  29A Suppl 5:S2-S5. 1993
  • Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin..  29A:1634. 1993
  • The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy..  29A Suppl 7:S23-S30. 1993
  • Aneuploid subpopulations in tumour-invaded lymph nodes from breast cancer patients..  28:357-362. 1992
  • Flow cytometric analysis of tumour-draining lymph nodes in breast cancer patients..  28:350-356. 1992
  • Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma 2018
  • CYP27A1/27HC/SREBP2 axis is a novel therapeutic target in prostate cancer 2016
  • Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC) 2016
  • AAV-shRNA vectors as an alternative therapy for human basal-like breast cancer 2016
  • Transcriptional regulation of prostate cancer metabolism 2016
  • 2007 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 2015
  • 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs) 2015
  • 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses 2015
  • 3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC) 2015
  • 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation 2015
  • 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC) 2015
  • P0124 Short-term and long-term outcomes for video-assisted thoracoscopic surgery and open lobectomy: Results from statistical analysis adjusting for treatment selection bias 2015
  • 250 Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes 2014
  • 322 Novel alternative splice variants as potential biomarkers and therapeutic targets in aggressive prostate cancer in men of African descent 2014
  • 465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC) 2014
  • 80 Determination of an oxidative stress gene signature in inflammatory breast cancer patient tumors and development of a novel redox modulatory strategy in overcoming chemotherapy resistance and mediating anti-tumor efficacy 2014
  • A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer 2013
  • Adverse events among patients treated for metastatic renal cell carcinoma (mRCC): Data from a real world, multicenter registry 2013
  • 101 Smac Mimetic Induces Apoptosis and Synergizes with TRAIL in Inflammatory Breast Cancer Cells in an IAP-Dependent and TNF-a-Independent Mechanism 2012
  • 172 Identification of Small Molecule Inhibitors of Wnt Secretion 2012
  • 443 Protein Typing of Circulating Microvesicles Allows Real-time Monitoring of Glioblastoma Therapy 2012
  • 76 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas 2012
  • 377 Extra-cellular Matrix Stiffness and Immune Cells Infiltrate Are Associated With Breast Tumor Phenotype 2012
  • OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts. 2011
  • 1411 POSTER Endpoints for Validation of Tumour Markers for Recurrence Risk -Recurrence-free Interval (RFI), Disease-free Survival (DFS), Overall Survival (OS), and Colon-cancer Specific Survival (CCSS) in CALGB 9581 2011
  • A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors 2003
  • Pharmacogenetics of the human glutathione S-transferase P1 gene and tumor response to chemotherapy 2002
  • GENE MODIFICATION OF PRIMARY TUMOR-CELLS FOR ACTIVE IMMUNOTHERAPY OF HUMAN BREAST AND OVARIAN-CANCER 1995
  • ANEUPLOID SUBPOPULATIONS IN TUMOR-INVADED LYMPH-NODES FROM BREAST-CANCER PATIENTS 1992
  • FLOW CYTOMETRIC ANALYSIS OF TUMOR-DRAINING LYMPH-NODES IN BREAST-CANCER PATIENTS 1992